Alisdair Coles (University of Cambridge, Cambridge, UK) shares exciting phase II findings that highlight the potential of retinoid-X receptor agonists to promote remyelination in relapsing-remitting multiple sclerosis. The interview focuses on his late-breaking presentation entitled: LB01.02 – Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis. Study identifiers: EudraCT number 2014-003145-99; ISRCTN14265371.
Questions
- Why has it taken so long to develop remyelination strategies in multiple sclerosis, and what are the potential advantages of this approach compared with existing disease-modifying therapies? (0:06)
- Could you give us an overview of the retinoid-X receptor agonist and its mechanism of promoting remyelination? (0:41)
- Could you tell us a little about the phase II study you are presenting and its findings? (1:13)
- At what stage in the disease course will remyelination strategies cease to be effective? (2:00)
- What will be the next step in the clinical development of this agent? (2:26)
Disclosures: Alasdair Coles reports receiving honoraria from Sanofi prior to 2017.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
